Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4529771
Max Phase: Preclinical
Molecular Formula: C52H82N2O13S
Molecular Weight: 975.30
Molecule Type: Unknown
Associated Items:
ID: ALA4529771
Max Phase: Preclinical
Molecular Formula: C52H82N2O13S
Molecular Weight: 975.30
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)C(N3CCS3(=O)=O)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1O
Standard InChI: InChI=1S/C52H82N2O13S/c1-32-15-11-10-12-16-34(3)42(54-25-26-68(54,62)63)31-40-21-19-38(7)52(61,67-40)49(58)50(59)53-24-14-13-17-41(53)51(60)66-44(35(4)29-39-20-22-43(55)45(30-39)64-8)23-18-33(2)28-37(6)47(57)48(65-9)46(56)36(5)27-32/h10-12,15-16,28,32-33,35-36,38-45,47-48,55,57,61H,13-14,17-27,29-31H2,1-9H3/b12-10+,15-11+,34-16+,37-28+/t32-,33+,35-,36-,38-,39+,40+,41+,42?,43-,44+,45-,47-,48+,52-/m1/s1
Standard InChI Key: ORALXZMWFFMYLU-TZBZESKCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 975.30 | Molecular Weight (Monoisotopic): 974.5538 | AlogP: 6.00 | #Rotatable Bonds: 6 |
Polar Surface Area: 206.51 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.96 | CX Basic pKa: | CX LogP: 6.99 | CX LogD: 6.99 |
Aromatic Rings: 0 | Heavy Atoms: 68 | QED Weighted: 0.16 | Np Likeness Score: 1.61 |
1. Abdel-Magid AF.. (2019) Rapalogs Potential as Practical Alternatives to Rapamycin., 10 (6): [PMID:31223435] [10.1021/acsmedchemlett.9b00215] |
Source(1):